Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey

Clinical and Translational Allergy
Anette BygumIOS Study Group

Abstract

Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of icatibant. We conducted descriptive analyses in younger (age < 65 years) versus elderly patients (age ≥ 65 years). Here, we report patient characteristics and safety-related findings. As of February 2018, 872 patients with C1-INH-HAE type I/II were enrolled, of whom 100 (11.5%) were ≥ 65 years old. Significant differences between elderly versus younger patients, respectively, were noted for median age at symptom onset (17.0 vs 12.0 years), age at diagnosis (41.0 vs 19.4 years), and delay between symptom onset and diagnosis (23.9 vs 4.8 years) (P ≤ 0.0001 for all). Median age at diagnosis was significantly higher in elderly patients regardless of family history (P < 0.0001). Throughout the study, icatibant was used to treat 6798 attacks in 574 patients, with 63 elderly patients reporting 715 (10.5%) ...Continue Reading

References

Feb 24, 2006·The American Journal of Medicine·Konrad BorkJochen Hardt
Sep 8, 2010·The New England Journal of Medicine·Marco CicardiWing-Tze Fan
Nov 30, 2011·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·William R LumryAvner Reshef
Feb 8, 2013·PloS One·Marcus MaurerUNKNOWN I O S Investigators
Oct 16, 2013·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Aleena Banerji
Nov 20, 2015·Clinical Pediatrics·Sandra C ChristiansenBruce L Zuraw
Jul 9, 2016·Clinical Reviews in Allergy & Immunology·Hilary Longhurst, Anette Bygum

❮ Previous
Next ❯

Citations

Dec 10, 2020·Clinical and Translational Allergy·J BousquetM Jutel
Apr 6, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Hilary J LonghurstLuis F Ensina
May 18, 2021·The World Allergy Organization Journal·Anna ValerievaHenriette Farkas

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01034969

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.